Japan · Delayed Price · Currency is JPY Nxera Pharma Earnings Call Transcripts
Fiscal Year 2026
-
NxWave platform drives a robust pipeline, with strong commercial growth in Japan and new rare disease assets like vamorolone. Two Phase II-ready programs are set for partnering, and key milestones from Neurocrine, Centessa, and collaborations are expected by 2026.
Fiscal Year 2025
-
FY 2025 saw revenue growth to JPY 29.6B, led by strong product sales, but operating losses due to higher R&D and restructuring costs. FY 2026 targets include profitability, cost reduction, and continued commercial growth, with upside from milestone deals and new product launches.
-
A focused restructuring prioritizes obesity and metabolic programs, streamlining operations and reducing costs while advancing key clinical assets and partnerships. Commercial growth in Japan and APAC remains strong, with significant cost savings and milestone revenues expected.
-
The company is restructuring to focus on best-in-class GPCR-targeted drugs, with a strong pipeline in oncology, neuropsychiatry, and metabolic diseases. Key partnered programs are advancing rapidly, and commercial products in Japan are outperforming expectations.
-
Net sales grew 19% year-on-year to JPY 150 billion, driven by PIVLAZ and QUVIVIC, though core operating profit declined due to higher R&D investment. The pipeline advanced with new obesity programs and clinical milestones, while the company maintains its FY 2025 sales targets and long-term growth ambitions.
-
Revenue more than doubled year-over-year, driven by strong Pivlaz sales and milestone payments, with core operating profit turning positive. 2025 profitability hinges on milestone income, especially from Boehringer Ingelheim, while Pivlaz and QUVIVIQ are set for continued growth.
-
The AGM confirmed strong financial results, approved all proposals including virtual AGMs and new director elections, and outlined ambitious growth and pipeline goals for 2030. The board and audit committee reported sound governance and internal controls.
-
Nxera Pharma unveiled its rebranding and outlined a strategy focused on GPCR innovation, global partnerships, and commercial expansion in Japan and APAC. The company highlighted strong financials, a robust pipeline with key late-stage assets, and ambitious growth targets for 2030.
Fiscal Year 2024
-
Revenue more than doubled year-over-year, driven by strong Pivlaz sales and milestone payments. 2025 profitability hinges on a major partnership trigger, while both Pivlaz and Quviviq are set for continued growth in Japan and APAC.
-
Ambitious 2030 targets include JPY 50 billion revenue and five product launches, with strong progress in neurology and immunology pipelines. PIVLAZ and QUVIVIQ drive growth, while cost efficiencies and strategic partnerships enhance R&D and financial performance.
-
Revenue and core operating profit surged year-over-year, driven by new partnerships, milestone payments, and strong PIVLAZ sales. Key pipeline programs advanced, with major data and regulatory events expected in the second half. Profitability remains dependent on milestone events.